From New Mechanisms to New Standards of Care
Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 13 Feb 2019
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
News / 08 Feb 2019
Summit Therapeutics to Present at the BIO CEO & Investor Conference
News / 10 Jan 2019
Completion of $25 million Subscription
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
For Investors
Visit our dedicated section for investors that contains the latest available financial and regulatory information
Latest Event
Listen to the BIO CEO & Investor Conference presentation
Our Discuva Platform
Our technology platform is at the heart of our research to develop new mechanism antibiotics